Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: Update of the 2005 evidence-based review

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 4, 2012, Pages 505-522

  Oliansky, Denise M ^a   Camitta, Bruce ^b   Gaynon, Paul ^c   Nieder, Michael L ^d   Parsons, Susan K ^e   Pulsipher, Michael A ^f   Dillon, Hildy ^g   Ratko, Thomas A ^h   Wall, Donna ⁱ   McCarthy Jr , Philip L ^a   Hahn, Theresa ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b CHILDREN S HOSPITAL OF WISCONSIN   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^e TUFTS MEDICAL CENTER   (United States)

^f UNIVERSITY OF UTAH   (United States)

^g The Leukemia & Lymphoma Society   (United States)

^h Blue Cross and Blue Shield Technology Evaluation Center   (United States)

ⁱ UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Acute lymphoblastic leukemia; Evidence based review; Hematopoietic stem cell transplantation; Pediatric; Therapy

Indexed keywords

ANTILEUKEMIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; IMATINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW CELL; CANCER CHEMOTHERAPY; CHILDHOOD CANCER; DISEASE FREE SURVIVAL; EVIDENCE BASED PRACTICE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; LEUKEMIA REMISSION; LIVING DONOR; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PROGNOSIS; REVIEW; RISK FACTOR; TREATMENT FAILURE; TREATMENT INDICATION; UNRELATED DONORS; WHOLE BODY RADIATION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; EVIDENCE-BASED MEDICINE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; REMISSION INDUCTION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84858074468     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.12.585     Document Type: Review

References (57)

1. Hahn T., Wall D., Camitta B., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. Biol Blood Marrow Transplant 2005, 11:823-861.
2. Ribera J.M., Ortega J.J., Oriol A., et al. Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 trial. J Clin Oncol 2007, 25:16-24.
3. Aricò M., Schrappe M., Hunger S.P., et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol 2010, 28:4755-4761.
4. Balduzzi A., De Lorenzo P., Schrauder A., et al. Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: the impact of the waiting time. Haematologica 2008, 93:925-929.
5. Mann G., Attarbaschi A., Schrappe M., et al. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood 2010, 116:2644-2650.
6. Schrauder A., Reiter A., Gadner H., et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol 2006, 24:5742-5749.
7. Schultz K.R., Bowman W.P., Aledo A., et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol 2009, 27:5175-5181.
8. Aricò M., Valsecchi M.G., Camitta B., et al. Outcome of treatment in children with Philadelphia chromosome positive childhood acute lymphoblastic leukemia. N Engl J Med 2000, 342:998-1006.
9. Wheeler K.A., Richards S.M., Bailey C.C., et al. Bone marrow transplantation versus chemotherapy in the treatment of very high-risk childhood acute lymphoblastic leukemia in first remission: results from Medical Research Council UKALL X and XI. Blood 2000, 96:2412-2418.
10. Uderzo C., Valsecchi M.G., Balduzzi A., et al. Allogeneic bone marrow transplantation versus chemotherapy in high-risk childhood acute lymphoblastic leukaemia in first remission. Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP) and the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol 1997, 96:387-394.
11. Pui C.H., Gaynon P.S., Boyett J.M., et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002, 359:1909-1915.
12. Eapen M., Raetz E., Zhang M.J., et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood 2006, 107:4961-4967.
13. Eapen M., Zhang M.J., Devidas M., et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with acute lymphoblastic leukemia in a second remission after an isolated central nervous system relapse: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Leukemia 2008, 22:281-286.
14. Malempati S., Gaynon P.S., Sather H., La M.K., Stork L.C. Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952. J Clin Oncol 2007, 25:5800-5807. for the Children's Oncology Group.
15. Tallen G., Ratei R., Mann G., et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol 2010, 28:2339-2347.
16. Saarinen-Pihkala U.M., Heilmann C., Winiarski J., et al. Pathways through relapses and deaths of children with acute lymphoblastic leukemia: role of allogeneic stem-cell transplantation in Nordic data. J Clin Oncol 2006, 24:5750-5762.
17. Einsiedel H.G., von Stackelberg A., Hartmann R., et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. J Clin Oncol 2005, 23:7942-7950.
18. Gaynon P.S., Harris R.E., Altman A.J., et al. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941. J Clin Oncol 2006, 24:3150-3156.
19. Barrett A.J., Horowitz M.M., Pollock B.H., et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Eng J Med 1994, 331:1253-1258.
20. Wheeler K., Richards S., Bailey C., Chessells J. Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: the MRC UKALL X experience. Medical Research Council Working Party on Childhood Leukaemia. Br J Haematol 1998, 101:94-103.
21. Uderzo C., Valsecchi M.G., Bacigalupo A., et al. Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology Association. J Clin Oncol 1995, 13:352-358.
22. Harrison G., Richards S., Lawson S., et al. Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. MRC Childhood Leukaemia Working Party. Ann Oncol 2000, 11:999-1006.
23. Borgmann A., von Stackelberg A., Hartmann R., et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood 2003, 101:3835-3839.
24. Tomblyn M.B., Arora M., Baker K.S., et al. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. J Clin Oncol 2009, 27:3634-3641.
25. Smith A.R., Baker K.S., DeFor T.E., Verneris M.R., Wagner J.E., Macmillan M.L. Hematopoietic cell transplantation for children with acute lymphoblastic leukemia in second complete remission: similar outcomes in recipients of unrelated marrow and umbilical cord blood versus marrow from HLA-matched sibling donors. Biol Blood Marrow Transplant 2009, 15:1086-1093.
26. Kennedy-Nasser A.A., Bollard C.M., Myers G.D., et al. Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant 2008, 14:1245-1252.
27. Muñoz A., Diaz-Heredia C., Diaz M.A., et al. Allogeneic hemopoietic stem cell transplantation for childhood acute lymphoblastic leukemia in second complete remission-similar outcomes after matched related and unrelated donor transplant: a study of the Spanish Working Party for Blood and Marrow Transplantation in Children (Getmon). Pediatr Hematol Oncol 2008, 25:245-259.
28. Sanders J.E., Im H.J., Hoffmeister P.A., et al. Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia. Blood 2005, 105:3749-3756.
29. Roy A., Bradburn M., Moorman A.V., et al. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. Br J Haematol 2005, 129:35-44.
30. Badell I., Muñoz A., Ortega J.J., et al. Long-term outcome of allogeneic or autologous haemopoietic cell transplantation for acute lymphoblastic leukaemia in second remission in children. GETMON experience 1983-1998. Bone Marrow Transplant 2005, 35:895-901.
31. Stern M., Ruggeri L., Mancusi A., et al. Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood 2008, 112:2990-2995.
32. Eapen M., Rubinstein P., Zhang M.J., et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007, 369:1947-1954.
33. Afify Z., Hunt L., Green A., Guttridge M., Cornish J., Oakhill A. Factors affecting the outcome of stem cell transplantation from unrelated donors for childhood acute lymphoblastic leukemia in third remission. Bone Marrow Transplant 2005, 35:1041-1047.
34. Burke M.J., Cao Q., Trotz B., et al. Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer 2009, 53:1289-1294.
35. Marks D.I., Forman S.J., Blume K.G., et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant 2006, 12:438-453.
36. Gassas A., Sung L., Saunders E.F., Doyle J.J. Comparative outcome of hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia following cyclophosphamide and total body irradiation or VP16 and total body irradiation conditioning regimens. Bone Marrow Transplant 2006, 38:739-743.
37. Bunin N., Aplenc R., Kamani N., Shaw K., Cnaan A., Simms S. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant 2003, 32:543-548.
38. Davies S.M., Ramsay N.K., Klein J.P., et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 2000, 18:340-347.
39. Weisdorf D.J., Woods W.G., Nesbit M.E., et al. Allogeneic bone marrow transplantation for acute lymphoblastic leukaemia: risk factors and clinical outcome. Br J Haematol 1994, 86:62-69.
40. Balduzzi A., Bonanomi S., Valsecchi M.G., et al. Autologous purified peripheral blood SCT in childhood low-risk relapsed ALL. Bone Marrow Transplant 2011, 46:217-226.
41. Diaz M.A., Gonzalez-Vicent M., Gonzalez M.E., et al. Long-term outcome of allogeneic PBSC transplantation in pediatric patients with hematological malignancies: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) and the Spanish Group for Allogeneic Peripheral Blood Transplantation (GETH). Bone Marrow Transplant 2005, 36:781-785.
42. Diaz M.A., Gonzalez-Vicent M., Ramirez M., et al. Allogeneic cord blood transplantation in children with hematological malignancies: a long-term follow-up single-center study. Pediatr Hematol Oncol 2009, 26:165-174.
43. Elorza I., Palacio C., Dapena J.L., Gallur L., Sánchez de Toledo J., Díaz de Heredia C. Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia. Haematologica 2010, 95:936-941.
44. Iori A.P., Arcese W., Milano F., et al. Unrelated cord blood transplant in children with high-risk acute lymphoblastic leukemia: a long-term follow-up. Haematologica 2007, 92:1051-1058.
45. Klingebiel T., Cornish J., Labopin M., et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood 2010, 115:3437-3446.
46. Petterson T.E., Gabriel M., Tiedemann K., et al. Outcome following unrelated cord blood transplant in 136 patients with malignant and non-malignant diseases: a report from the Australian and New Zealand children's haematology and oncology group. Bone Marrow Transplant 2009, 43:207-215.
47. Satwani P., Sather H., Ozkaynak F., et al. Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblasticleukemia: a Children's Oncology Group Study report. Biol Blood Marrow Transplant 2007, 13:218-227.
48. Sawczyn K.K., Quinones R., Malcolm J., et al. Cord blood transplant in childhood ALL. Pediatr Blood Cancer 2005, 45:964-970.
49. Schechter T., Ishaqi K.M., Rojas M., Irina Z., Doyle J.J., Gassas A. Outcome of hematopoietic stem cell transplantation of children with very high risk acute lymphoblastic leukemia in first complete remission. Pediatr Transplant 2010, 14:377-382.
50. Talano J.M., Casper J.T., Camitta B.M., et al. Alternative donor bone marrow transplant for children with Philadelphia chromosome ALL. Bone Marrow Transplant 2006, 37:135-141.
51. Teuffel O., Schrauder A., Sykora K.W., et al. The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia. Bone Marrow Transplant 2005, 36:145-150.
52. Verneris M.R., Eapen M., Duerst R., et al. Reduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2010, 16:1237-1244.
53. Watanabe N., Matsumoto K., Yoshimi A., et al. Outcome of bone marrow transplantation from HLA-identical sibling donor in children with hematological malignancies using methotrexate alone as prophylaxis for graft-versus-host disease. Int J Hematol 2008, 88:575-582.
54. Rives S., Estella J., Camós M., et al. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation (SCT) improves early outcome in childhood Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Results of the Spanish Cooperative Group SHOP/SEHOP studies SHOP 94, SHOP 99 and SHOP 05. Blood 2010, 116:3247. Abstract.
55. Ruggeri A., Michel G., Dalle J.-H., et al. Impact of minimal residual disease at unrelated cord blood transplantation in children with acute lymphoblastic leukemia in remission: a study on behalf of Eurocord-EBMT and EBMT-PDWP. Blood 2010, 116:532. Abstract.
56. Tracey J., Zhang M.-J., Sobocinski K.A., et al. Transplant conditioning regimens and outcomes after allogeneic hematopoietic cell transplantation (HCT) in children and adolescents with acute lymphoblastic leukemia (ALL). Blood 2010, 116:3506. Abstract.
57. Koh K., Tomizawa D., Saito A.M., et al. Early phase administration of hematopoietic stem cell transplantation to prevent early relapse for infants with acute lymphoblastic leukemia and MLL gene rearrangement; a report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Trial MLL03. Blood 2010, 116:529. Abstract.